American journal of therapeutics
Cure8 research brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a case report related to Crohn's disease, Infliximab, Anti-TNF, and Complications. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAmerican journal of therapeutics
AuthorsNalakath A Uvais, Sabith M Thajudeen
InstitutionDepartment of Psychiatry, Iqraa International Hospital and Research Centre, Calicut, India; and.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 13, 2026, 12:00 AM
Content availableMetadata only
Conflict statement: The authors have no conflicts of interest to declare.
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
'Top-down' therapy linked to fivefold lower risk for abdominal surgery in Crohn's disease
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.